For Research Use Only. Not for Human Consumption.
Recorded market$81.54Recorded exact-size market estimate: 81.54 USD for one 10 mg container (8.154276 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$81.00Member price$69.0615.3% lessMembers save $12.48 on this item vs. recorded market
Stabilized GHRH analog for endocrine research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$6.91/mg15.3% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Orion Peptides Oct 11, 2026 UTC | One 10 mg container; 90.00 USD | $9.00/mg | powder; 6 in stock Price observation; no COA authentication is implied by inclusion. |
| Prism Labs Oct 11, 2026 UTC | One 10 mg container; 64.99 USD | $6.50/mg | powder; in_stock Price observation; no COA authentication is implied by inclusion. |
| Pure Bio Labs Oct 11, 2026 UTC | One 10 mg container; 124.99 USD | $12.50/mg | powder; Purchase option active Price observation; no COA authentication is implied by inclusion. |
| Beach Bio Research Oct 11, 2026 UTC | One 10 mg container; 40.00 USD | $4.00/mg | powder; Schema InStock; local delivery only Price observation; no COA authentication is implied by inclusion. |
| Glow Peptides Oct 11, 2026 UTC | One 10 mg container; 84.99 USD | $8.50/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Purity Collective Oct 11, 2026 UTC | One 10 mg container; 89.99 USD | $9.00/mg | powder; 57 in stock Price observation; no COA authentication is implied by inclusion. |
| Pepta Labs Oct 11, 2026 UTC | One 10 mg container; 66.58 USD | $6.66/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Durham Peptides Oct 11, 2026 UTC | One 10 mg container; 134.99 CAD | $9.49/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 11, 2026 UTC | One 10 mg container; 80.00 USD | $8.00/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 11, 2026 UTC | One 10 mg container; 79.00 USD | $7.90/mg | powder; In stock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Tesamorelin – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/tesamorelin-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/tesamorelin-10-mg/
A stabilized analog of growth-hormone-releasing hormone used in endocrine-axis and body-composition research models.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Tesamorelin is a GHRH analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Tesamorelin stimulates the growth-hormone pathway through a releasing-hormone mechanism. It is distinct from growth hormone itself, sermorelin and other modified GHRH products.
Current Egrifta WR and Egrifta SV formulations are not substitutable. Their product-specific preparation and exposure requirements should not be mixed.
Controlled studies show reductions in visceral abdominal fat in selected adults with HIV. Another small trial investigated liver fat in that population. These findings should not be restated as a general obesity treatment, a guaranteed reduction in body weight or approval for every form of fatty-liver disease.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Twenty-six-week randomized placebo-controlled trial in 412 adults with HIV and abdominal fat accumulation Reading scope: PubMed bibliographic record and abstract |
Visceral adipose tissue fell with tesamorelin while it rose slightly with placebo; IGF-1 increased and more participants stopped treatment because of adverse events. | The population and abdominal-fat endpoint differ from general obesity treatment and long-term cardiovascular outcomes. |
| Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Six-month randomized double-blind trial in 50 adults with HIV Reading scope: PubMed bibliographic record and abstract |
Visceral and liver fat decreased. Fasting glucose rose early, although the later difference was not statistically significant. | This small study does not establish a general fatty-liver indication, and an early glucose signal should not be omitted because of the later result. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Visceral fat measured by imaging is different from total weight on a scale. A product can affect one without delivering a comparable change in the other.
The label explicitly excludes general weight-loss management and says long-term cardiovascular safety has not been established. A favorable body-composition result is not proof of fewer heart attacks or improved survival.
IGF-1 and glucose changes matter to the treatment context. A growth-pathway marker should not be marketed solely as evidence that the intervention is working.
The current Egrifta WR label includes contraindications involving active malignancy and disruption of the hypothalamic-pituitary axis, along with IGF-1 and glucose-related monitoring.
A research summary cannot determine an individual’s suitability. The evidence comes from selected participants receiving clinical follow-up, not from unrestricted use for abdominal appearance.
Keep the original trial formulation and treatment duration attached to the result. A current formulation’s nominal amount should not be copied from an older study or a different Egrifta version.
Distinguish a change during active treatment from a persistent effect after stopping. Long-term maintenance and clinical outcomes require follow-up beyond an initial imaging result.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Identify the exact tesamorelin product and formulation. A GHRH-family assay or a sermorelin report is not an identity match.
If a listing invokes Egrifta evidence, determine whether it actually supplies that pharmaceutical product. A raw-powder assay does not establish formulation equivalence or substantiate the same finished-product claims.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. Its labeled purpose concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The key trials emphasize visceral fat.
No. The trial is a specific study in adults with HIV; a broader indication would need its own evidence and regulatory basis.
No. The current label specifically states that the formulations are not substitutable.
This companion to the Tesamorelin research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Keep the original trial formulation and treatment duration attached to the result. A current formulation’s nominal amount should not be copied from an older study or a different Egrifta version.
Distinguish a change during active treatment from a persistent effect after stopping. Long-term maintenance and clinical outcomes require follow-up beyond an initial imaging result.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.